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Abstract This randomized trial evaluated ferric carb-
oxymaltose without erythropoiesis-stimulating agents
(ESA) for correction of anemia in cancer patients with
functional iron deficiency. Patients on treatment for indo-
lent lymphoid malignancies, who had anemia [hemoglobin
(Hb) 8.5–10.5 g/dL] and functional iron deficiency [trans-
ferrin saturation (TSAT) B20 %, ferritin [30 ng/mL
(women) or[40 ng/mL (men)], were randomized to ferric
carboxymaltose (1,000 mg iron) or control. Primary end
point was the mean change in Hb from baseline to weeks 4,
6 and 8 without transfusions or ESA. Difficulties with
patient recruitment led to premature termination of the
study. Seventeen patients (8 ferric carboxymaltose and 9
control) were included in the analysis. In the ferric carb-
oxymaltose arm, mean Hb increase was significantly higher
versus control at week 8 (p = 0.021). All ferric carboxy-
maltose-treated patients achieved an Hb increase [1 g/dL
(control 6/9; p = 0.087), and mean TSAT was[20 % from
week 2 onwards. No treatment-related adverse events were
reported. In conclusion, ferric carboxymaltose without
ESA effectively increased Hb and iron status in this small
patient population.
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Introduction
Anemia and iron deficiency are frequent complications in
cancer patients, particularly in those undergoing chemo-
therapy [1]. Both correlate with poor performance status in
cancer patients, and anemia has been shown to be associ-
ated with shorter survival [1, 2].
Inadequate iron supply is a major component in the
pathogenesis of anemia in cancer patients [3].The estimated
prevalence of insufficient iron availability in cancer patients
ranges from 19–63 %, and functional iron deficiency (FID)
is much more common than absolute iron deficiency [1, 3].
FID occurs when release of iron from internal stores is
restricted (e.g., due to inflammation) or too slow to keep pace
with erythropoiesis [e.g., after treatment with erythropoi-
esis-stimulating agents (ESA)]. It is characterized by low
transferrin saturation (TSAT B 20 %) in spite of adequate
iron stores, while serum ferritin levels usually are elevated
[3, 4].
Present management of cancer-related anemia often
consists of red blood cell (RBC) transfusions or ESA
treatment [5]. However, at least 30 % of anemic cancer
patients do not respond to ESA treatment alone [6], and
over recent years, the evidence has accumulated that RBC
transfusions, as well as ESA use outside the current label
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and guidelines, can increase all-cause mortality [7–9].
Current guidelines therefore recommend preventing RBC
transfusions and using ESAs at the lowest effective dose
[10]. Randomized, controlled trials using intravenous (i.v.)
iron treatment in combination with ESA showed increased
hematological response, reduced RBC transfusion and ESA
dose requirements, and faster correction of cancer-related
anemia compared with ESA alone or with oral iron [11].
Initiation of anemia treatment with i.v. iron alone could be
an interesting therapeutic option for patients with cancer-
related anemia. So far, there is evidence on the benefit of
i.v. iron alone in three randomized controlled studies in
patients with gynecological cancers [12–14] and two
observational studies [15, 16].
In this study for the first time, a distinction was made
between the two basic types of iron deficiency (absolute or
functional). Here, we evaluated the efficacy of i.v. ferric
carboxymaltose (FCM) without the addition of ESA as
treatment for chemotherapy-induced anemia in patients
with lymphoid malignancies and functional iron deficiency
receiving antineoplastic therapy.
Materials and methods
This randomized, controlled, open-label, prospective trial
included 11 recruiting sites across four countries (Austria,
Germany, Russia, and Sweden). The study was registered
(ClinicalTrials.gov Identifier: NCT01101399) and con-
ducted in accordance with the Declaration of Helsinki and
approved by Independent Ethics Committees.
Included were adult patients with lymphoid malignancies
(indolent non-Hodgkin’s lymphoma, multiple myeloma, or
chronic lymphocytic leukemia), anemia [hemoglobin (Hb)
8.5–10.5 g/dL], and FID [TSAT B 20 % and serum ferritin
[30 ng/mL (women) or [40 ng/mL (men)] who had
received antineoplastic therapy for C8 weeks (or two
cycles) prior to inclusion (see supplementary data for a
comprehensive list of inclusion/exclusion criteria).
Based on a predefined, computer-generated randomiza-
tion list, patients were randomized 1:1 to FCM (Ferinject,
Vifor Pharma, Switzerland) or no anemia treatment (con-
trols; symptomatic management according to local insti-
tutional practice). Patients [50 kg received a single
infusion of 1,000 mg iron at day 1 of the next antineo-
plastic therapy cycle, and patients \50 kg received two
infusions of 500 mg iron each (day 1 and week 2).
Primary end point was the mean Hb change from
baseline to week 8 without use of transfusions or ESA.
Secondary end points included safety, Hb response
(increase C 1.0 g/dL) and correction (Hb C 11.0 g/dL) at
any week, median time to Hb response and changes in
hematologic variables.
The planned sample size of 40 patients (20 per group)
was calculated to detect an expected difference in Hb of
1.0 g/dL (standard deviation 1.5 g/dL) at a 1-sided alpha of
0.05 and a power of 68 %. These data were derived from a
large observational study in cancer patients who had
received 500–4,000 mg of FCM for the treatment of iron-
restricted erythropoiesis and anemia, and achieved a
C1.0 g/dL mean Hb increase from baseline by week 4 [15].
The primary efficacy variable was analyzed using a
mixed effects model for repeated measures (MMRM).
Comparisons at weeks 8, 6, and 4 were made using a
hierarchical step-down procedure with the primary end
point at week 8. Exact logistic regression, adjusted for
baseline Hb, was used for all tests based on proportions.
Time-to-event analyses were investigated using Kaplan–
Meier survival plots with log-rank tests for comparisons.
No adjustment was made for multiplicity.
Difficulties with patient recruitment led to premature
study termination, after randomization of only half of the
planned patients.
Results
Of 34 screened patients, 19 were randomized (safety set: 8
FCM, 11 controls) and 17 had post-baseline efficacy data
available for primary endpoint analysis [full analysis set
(FAS): 8 FCM, 9 controls; Fig. 1]. The per-protocol set
(FAS patients with no major protocol deviations) included
12 patients (5 FCM, 7 controls). Baseline patient charac-
teristics were comparable between the FCM and the control
group (Table 1).
In the FCM group, five patients received a single FCM
administration (1,000 mg iron) and three received two
FCM administrations (500 mg iron per dose).
No patient required blood transfusion or ESA treatment
during the study period. In the FAS population, FCM-
treated patients had a greater mean Hb increase from
baseline compared with control patients at all post-baseline
visits, with a statistically significant difference at week 8
(p = 0.021 vs. controls; Fig. 2a). Thus, the primary end
point was met despite the small number of patients. Median
Hb increase from baseline to week 8 was 2.1 g/dL [range
0.2–3.5 g/dL] in FCM-treated patients vs. 0.9 g/dL [range
0.3–2.2 g/dL] in the control group. In the per-protocol set,
the primary endpoint analysis showed significantly higher
Hb increases in the FCM versus control group from week 4
onwards (all p B 0.005; Fig. 2b).
All (8/8) FCM-treated patients compared to 66.7 % (6/
9) of control patients achieved an Hb response (p = 0.954).
Median time to response was 2.3 [range 0.6–7.3] weeks in
FCM-treated versus 4.4 [range 1.0–8.1] weeks in control
patients (p = 0.087). Hb was corrected in 87.5 % (7/8) of
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FCM-treated and 55.6 % (5/9) of control patients
(p = 0.105). In the FCM group, a median Hb of 11.8 g/dL
[range 9.4–13.1 g/dL] was achieved at week 6 and
remained stable until end of study (11.9 g/dL at week 8). In
the control group, median Hb remained below 11.0 g/dL at
all time points.
Ferritin and TSAT increased faster and to significantly
higher levels in FCM-treated patients vs. controls
(Fig. 2c, d). In the FCM group, a median TSAT of 28 %
[range 19–38 %] was reached at week 2 and remained
stable until end of study, whereas in the control group,
median TSAT remained below 20 % at all time points.
Changes in other tested variables (erythropoietin, hepci-
din-25, and interleukin-6) were statistically not signifi-
cantly different between treatment groups (supplementary
Table S1).
As expected for an open-label comparison of active
treatment versus controls, more treatment-emergent
adverse events (TEAEs) were reported in the FCM than in
the control group (FCM: 12 TEAEs in 5 patients; controls:
2 TEAEs in 1 patient; supplementary Table S2 and S3).
However, none of the reported TEAEs were considered
related to the study drug or led to discontinuation. No
hypersensitivity reactions were observed.
Discussion
Data from randomized controlled studies on the effect of i.v.
iron as sole anemia therapy in cancer patients are still scarce,
and this is the first randomized controlled trial to investigate
whether i.v. iron can overcome the iron sequestration which
is a consequence of the inflammatory nature of malignant
disease. A single dose of FCM without concomitant ESA
therapy resulted in significantly increased Hb levels which
were maintained for at least 8 weeks in this population of
cancer patients with lymphoid malignancies, anemia, and
functional iron deficiency receiving antineoplastic therapy.
There was a large mean increase in Hb from baseline to
week 8 in the FCM group (2.1 g/dL) and the primary end
point was met despite the small number of evaluable
patients. Using the per-protocol population, the primary
endpoint analysis showed statistically significantly higher
Hb increases in the FCM vs. control group from week 4
onwards. TSAT and serum ferritin increased rapidly and
remained high from the first post-treatment visit onwards.
No patient required a blood transfusion or an ESA treat-
ment during the study period.
We observed a slight Hb increase in the controls at week
6–8 (Fig. 2a, b), which may be related to fluctuations in Hb
Randomized (n=19)
Allocated to control (n=11)
Received standard care (n=11)
Analyzed
Safety set (n=11)
Full analysis set (n=9)*
Per protocol set (n=7)




Full analysis set (n=8)
Per protocol set (n=5)
Screened (n=34)
Major protocol violations (4)
• Not meeting the definition of iron-
restricted erythropoiesis (2)
• Receiving anemia treatment within  
4 weeks before inclusion (1)
• Having the last visit outside the 
Week 8 visit window (1)
Major protocol violations (3)
• Not meeting the definition of iron-
restricted erythropoiesis (3)
Fig. 1 Patient flow diagram
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levels and/or tumor regression. The latter would be in-line
with the observed decrease in ferritin and concomitant
TSAT increase in the controls, possibly indicating reduced
inflammation and consequently increased availability of
iron for erythropoiesis.
Of note, since this study was prematurely terminated
due to difficulties with patient recruitment, only half of the
planned patients were randomized. Thus, as a consequence,
the power of the study is below the adequate power, and
therefore, only limited interpretation of the data is possible.
However, our results are in-line with those of a large
observational study in FCM-treated anemic cancer patients
(n = 420; 233 patients received FCM alone), which
showed improvement in median Hb from 10.0 g/dL to
above 11 g/dL within 5 weeks and a median Hb increase of
1.4 g/dL. This improvement was achieved without trans-
fusions and/or ESA treatment [15]. In addition, three ran-
domized, controlled clinical trials have shown that i.v. iron
alone significantly reduced transfusion requirements in
patients with gynecological cancers [12–14]. A single-arm
pilot study with i.v. iron sucrose in anemic, non-iron-
deficient cancer patients undergoing chemotherapy therapy
without ESA use, showed a significant improvement in Hb
levels compared with baseline [16]. However, in these
studies no distinction was made between absolute iron
deficiency (low serum ferritin) and FID, while in the
present study, only patients with FID were included.
Current guidelines for cancer and chemotherapy-induced
anemia recommend preventing blood transfusions and using
ESAs with the lowest effective dose and in approved indi-
cations only, based on safety concerns associated with both
treatments [10, 17]. In line with these recommendations, the
use of i.v. iron alone in anemia therapy may reduce or even
prevent the need for ESAs and RBC.
In conclusion, our study clearly indicates that i.v. iron
alone corrects anemia and FID in cancer patients undergoing
Table 1 Baseline patient characteristics (safety set)
FCM (n = 8) Controlsd (n = 11)
Male, n (%) 5 (62.5) 7 (63.6)
Age (years, median [range]) 69.5 [41–79] 71.0 [26–88]
Weight (kg, median [range]) 67.8 [59.0–103.7] 66.4 [49.0–78.0]
Baseline Hb and iron status Hb (g/dL, median [range]) 9.5 [9.0–10.5] 9.8 [8.4–10.6]
Ferritin (ng/mL, median [range])a 216 [65–800] 322 [8–707]
TSAT (%, median [range])a 16 [3–35] 18 [0–31]
Previous anti-anemic therapyb, n (%) Transfusion 3 (37.5) 1 (9.1)
ESA 0 1 (9.1)
iron 0 1 (9.1)
Tumor type, n (%) Multiple myeloma 6 (75.0) 5 (45.5)
Chronic lymphocytic leukemia 1 (12.5) 1 (9.1)
Non-Hodgkin’s lymphoma 1 (12.5) 5 (45.5)










Corticosteroids for systemic use 7 6
Dexamethasone 4 3
Prednisone 3 4
a Patients with baseline TSAT[20 % and ferritin B30 (women) or B40 ng/mL (men) were excluded from the per-protocol population (3 FCM,
2 Control)
b [4 weeks prior to baseline
c As per protocol, patients had to be receiving cancer treatment
d Symptomatic management according to local institutional practice
302 Page 4 of 6 Med Oncol (2014) 31:302
123
antineoplastic therapy. Further, appropriately powered and
controlled studies are warranted to validate these results.
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baseline in Hb and iron status
Med Oncol (2014) 31:302 Page 5 of 6 302
123
13. Athibovonsuk P, Manchana T, Sirisabya N. Prevention of blood
transfusion with intravenous iron in gynecologic cancer patients
receiving platinum-based chemotherapy. Gynecol Oncol. 2013;
131(3):679–82.
14. Kim YT, Kim SW, Yoon BS, Cho HJ, Nahm EJ, Kim SH, et al.
Effect of intravenously administered iron sucrose on the pre-
vention of anemia in the cervical cancer patients treated with
concurrent chemoradiotherapy. Gynecol Oncol. 2007;105(1):
199–204.
15. Steinmetz T, Tschechne B, Harlin O, Klement B, Franzem M,
Wamhoff J, et al. Clinical experience with ferric carboxymaltose
in the treatment of cancer- and chemotherapy-associated anae-
mia. Ann Oncol. 2013;24(2):475–82.
16. Abdel-Razeq H, Abbasi S, Saadi I, Jaber R, Abdelelah H.
Intravenous iron monotherapy for the treatment of non-iron-
deficiency anemia in cancer patients undergoing chemotherapy: a
pilot study. Drug Des Dev Ther. 2013;7:939–44.
17. Bokemeyer C, Aapro MS, Courdi A, Foubert J, Link H, Oster-
borg A, et al. EORTC guidelines for the use of erythropoietic
proteins in anaemic patients with cancer: 2006 update. Eur J
Cancer. 2007;43(2):258–70.
302 Page 6 of 6 Med Oncol (2014) 31:302
123
